ProCE Banner Activity

Using Immunotherapy to Treat Advanced Squamous NSCLC: Where Are We Now?

Clinical Thought
How do you manage patients with advanced squamous NSCLC in the era of immunotherapy? In this commentary, H. Jack West, MD, discusses the latest treatment options for advanced squamous NSCLC involving immune checkpoint inhibitors.

Released: February 24, 2020

Expiration: February 22, 2021

Share

Faculty

Heather J. Jackson

Heather J. Jackson, PhD, FNP-BC, NEA-BC, FAANP

Associate Professor
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University School of Nursing
Administrative Director of Advanced Practice
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Celgene

Loxo Oncology subsidiary of Eli Lilly

Partners

GRACE

ProCE Banner

Faculty Disclosure

Primary Author

Heather J. Jackson, PhD, FNP-BC, NEA-BC, FAANP

Associate Professor
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University School of Nursing
Administrative Director of Advanced Practice
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

H. Jack West, MD, has disclosed that he has received consulting fees from AstraZeneca, Celgene, Genentech/Roche, Merck, and Takeda and fees for non-CME/CE services from AstraZeneca, Merck, and Takeda.